雷替曲塞联合伊立替康治疗一线方案失败或术后复发转移胰腺癌的疗效  

Effect of raltitrexed combined with irinotecan therapy on pancreatic cancer patients who had failed first-line treatment or postoperative recurrence and metastasis

作　　者：王会忠[1] 王震[1] 阎凤霞[1] 

机构地区：[1]山东省青岛市黄岛区人民医院内三科,青岛266000

出　　处：《中国肿瘤临床与康复》2015年第9期1060-1062,共3页Chinese Journal of Clinical Oncology and Rehabilitation

摘　　要：目的探讨雷替曲塞联合伊立替康治疗一线方案失败或术后复发转移的胰腺癌的临床疗效。方法选择70例吉西他滨治疗失败或手术复发转移的胰腺癌患者作为研究对象,给予雷替曲塞和伊立替康联合治疗,采用实体瘤疗效评价标准（RECIST）3.0评价近期疗效;观察肿瘤进展时间（TTP）和不良反应。结果全组患者的临床有效率为45.7%,疾病控制率为88.6%。患者不良反应主要表现为中性粒细胞减少、胃肠道反应、疲乏,多为1~2级。全组患者的TTP为（7.2±1.1）个月。结论雷替曲塞联合伊立替康治疗一线方案失败或手术后复发转移的胰腺癌患者具有一定临床疗效,不良反应轻,可延长患者生存时间。Objective To explore the clinical effect of raltitrexed combined with irinotecan therapy on pancreatic cancer patients who had failed first-line treatment or postoperative recurrence and metastasis.Methods Totally 70 pancreatic cancer patients with failure to gemcitabine or relapse and metastasis after operation were selected as research object. Raltitrexed and irinotecan were combined to treat weekly; Response Evaluation Criteria in Solid Tumors（ RECIST） 3. 0 was applied to evaluate the short-term curative effect after two periods; Follow-up visit was completed every one or two months,and summarized the time to tumor progression（ TTP）. Results Clinical effective rate（ RR） of pancreatic cancer patients after treatment by raltitrexed combined with irinotecan was 45. 7%,and disease control rate（ DCR） was 88. 6%;Side effects of patients during the treatment period were mainly neutropenia,gastrointestinal reaction and fatigue,which mostly were one to two degree; Results of follow-up visit showed that average median TTP of patients was（ 7. 2 ± 1. 1） months after treatment. Conclusion Treatment of raltitrexed combined with irinotecan could improve the clinical effect of pancreatic cancer patients who had failed first-line treatment or postoperative recurrence and metastasis,decrease the side effects and prolong the survival time,which is worthy used widely in clinical.

关 键 词：胰腺肿瘤 雷替曲塞 伊立替康 复发 转移 

分 类 号：R735.9[医药卫生—肿瘤]